We report a case of bilateral renal cell cancer and multiple lung metastasis who was first treated with left radical nephrectomy and nephron-sparing surgery of the right kidney. Consecutive interleukin-2 administration achieved partial response in lung disease and residual tumors were surgically removed. The disease-free state has continued for 33 months.

1.
Yagoda A: Chemotherpay of renal cell carcinoma: 1983–1989. Semin Urol 1989;7:199–202.
2.
Forman JD: The role of radiation therapy in the management of carcinoma of the kidney. Semin Urol 1989;7:195–198.
3.
Savage PD: Renal cell carcinoma. Curr Opin Oncol 1995;7:275–280.
4.
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889–897.
5.
Fisher RI, Coltman CA Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, et al: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 1988;108:518–523.
6.
Margolon KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, et al: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486–498.
7.
Usui A: Study on adoptive immunotherapy in patients with renal cell carcinoma. II. Plasmapheresis with adoptive immunotherapy using LAK cells and IL-2. Jpn J Urol 1990;81:1058–1064.
8.
Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T: Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin-2. Jpn J Urol 1991;82:395–404.
9.
Fujioka T, Nomura K, Hasegawa M, Ishikura K, Kubo T: Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma. Br J Urol 1994;73:23–31.
10.
Geertsen PF, Hermann GG, von der Maase H, Steven K: Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: A single-center phase II study. J Clin Oncol 1992;10:753–759.
11.
Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metatstatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688–696.
12.
Tomita Y, Terunuma M, Nishiyama T, Sato S: Treatment of patients with advanced renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide. J Jpn Soc Cancer Ther 1992;27:1789–1795.
13.
Tomita Y, Katagiri A, Saito K, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K: Adoptive immunotherapy using interleukin-2, lymphokine-activated killer cells and cyclophosphamide for advanced renal cell cancer patients; long term results. Int J Urol, in press.
14.
Fleischmann JD, Kim B: Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 1991;145:938–941.
15.
Tomita Y, Imai T, Saito K, Tanikawa T, Takeda M, Takahashi K: Nephron-sparing surgery for synchronous and asynchronous bilateral renal cell cancer: A procedure using intraoperative ultrasonography, argon beam coagulator and fibrin glue. Jpn J Urol 1996;87:766–771.
16.
Kim B, Louie AC: Surgical resection following interleukin-2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 1992;127:1343–1349.
17.
Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A: Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992;10:960–968.
18.
Rafla S: Renal cell carcinoma. Natural history and results of treatment. Cancer 1970;25:26–40.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.